{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:08Z","timestamp":1790659628017,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaci.2019.02.029","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T13:21:58Z","timestamp":1552569718000},"page":"216-223.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1"],"prefix":"10.1016","volume":"144","author":[{"given":"Ana Isabel","family":"Tabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Torrecillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Blanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.02.029_bib1","series-title":"Microfungi","author":"Gravesen","year":"1994"},{"key":"10.1016\/j.jaci.2019.02.029_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4168\/aair.2015.7.3.205","article-title":"Mold allergens in respiratory allergy: from structure to therapy","volume":"7","author":"Twaroch","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2019.02.029_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/09031936.06.00074705","article-title":"The link between fungi and severe asthma: a summary of the evidence","volume":"27","author":"Denning","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2019.02.029_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaci.2005.05.030","article-title":"Dustborne Alternaria alternata antigens in US homes: results from the National Survey of Lead and Allergens in Housing","volume":"116","author":"Salo","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.envint.2016.01.003","article-title":"Alternaria alternata allergens: markers of exposure, phylogeny and risk of fungi-induced respiratory allergy","volume":"89-90","author":"Gabriel","year":"2016","journal-title":"Environ Int"},{"key":"10.1016\/j.jaci.2019.02.029_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaci.2011.10.008","article-title":"Predominant localization of the major Alternaria allergen Alt a 1 in the cell wall of airborne spores","volume":"129","author":"Twaroch","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaci.2012.03.047","article-title":"Alternaria alternata allergen Alt a 1: a unique \u03b2-barrel protein dimer found exclusively in fungi","volume":"130","author":"Chruszcz","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.anai.2016.05.012","article-title":"Fungal raw materials used to produce allergen extracts","volume":"118","author":"Esch","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib9","first-page":"154","article-title":"Correlation between Alt a 1 levels and clinical symptoms in Alternaria alternata\u2014monosensitized patients","volume":"22","author":"Brito","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.fgb.2004.10.009","article-title":"Alt a 1 allergen homologs from Alternaria and related taxa: analysis of phylogenetic content and secondary structure","volume":"42","author":"Hong","year":"2005","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.jaci.2019.02.029_bib11","first-page":"892","article-title":"Identification of allergens homologous to Alt a 1 from Stemphylium botryosum and Ulocladium botryrtis","volume":"49","author":"Gutierrez-Rodr\u00edguez","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.jaci.2019.02.029_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4168\/aair.2016.8.5.428","article-title":"Orthologous allergens and diagnostic utility of major allergen Alt a 1","volume":"8","author":"Moreno","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2019.02.029_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1710-1492-6-27","article-title":"Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study","volume":"6","author":"Prieto","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib14","unstructured":"EMEA\/CHMP\/BWP\/304831\/2007. Guideline on allergen products: production and quality issues. EMEA, London, 20 November 2008."},{"key":"10.1016\/j.jaci.2019.02.029_bib15","unstructured":"EMEA\/CHMP\/EWP\/18504\/2006. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. EMEA, London, 20 November 2008."},{"key":"10.1016\/j.jaci.2019.02.029_bib16","unstructured":"EMEA\/CPMP\/ICH\/135\/95. Note for guidance on good clinical practices."},{"key":"10.1016\/j.jaci.2019.02.029_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2009.10.060","article-title":"Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System","volume":"125","author":"Cox","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1398-9995.1998.tb04082.x","article-title":"Immunotherapy as an effective tool in allergy treatment","volume":"53","author":"Malling","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.02.029_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s40629-015-0051-7","article-title":"Authorised allergen products for intracutaneous testing may no longer be available in Germany. Allergy textbooks have to be re-written","volume":"24","author":"Klimek","year":"2015","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaci.2019.02.029_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0091-6749(90)90156-X","article-title":"Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract","volume":"85","author":"Horst","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1157\/13075696","article-title":"Evaluation of paediatric tolerance to an extract of Alternaria alternata under two\u00a0treatment regimes. A\u00a0multicenter study","volume":"33","author":"Mart\u00ednez-Ca\u00f1avate","year":"2005","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.jaci.2019.02.029_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1399-3038.2007.00589.x","article-title":"Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety","volume":"19","author":"Tabar","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1399-3038.2007.00587.x","article-title":"Double-blind, placebo-controlled Alternaria alternata immunotherapy: in\u00a0vivo and in\u00a0vitro parameters","volume":"19","author":"Lizaso","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jaci.2010.11.036","article-title":"Efficacy and safety of immunotherapy for allergies to Alternaria alternate in children","volume":"127","author":"Kuna","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib26","first-page":"279","article-title":"Variability of Alt a 1 expression by different strains of Alternaria alternata","volume":"91","author":"Mart\u00ednez","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mai.2001.114118","article-title":"Quantitation of the major fungal allergens, Alt a 1 and Asp f 1 in commercial allergenic products","volume":"107","author":"Vailes","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2003.11.024","article-title":"Manufacturing and standardizing allergen products","volume":"113","author":"Esch","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaci.2005.05.017","article-title":"Prevalence of positive skin test responses to 10 common allergens in the US population: Results from the Third National Health and Nutrition Examination Survey","volume":"116","author":"Arbes","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib30","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1398-9995.2004.00501.x","article-title":"Methodology and quality of immunotherapy trials","volume":"59","author":"Malling","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.02.029_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s40629-014-0032-2","article-title":"Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases","volume":"23","author":"Pfaar","year":"2014","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaci.2019.02.029_bib32","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1365-2222.2003.01821.x","article-title":"High-dose exposure to cat is associated with clinical tolerance\u2014a modified Th2 immune response?","volume":"33","author":"Kaul","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.02.029_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000053689","article-title":"Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response","volume":"124","author":"Platts-Mills","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1398-9995.1993.tb00749.x","article-title":"Allergen-specific IgG4 in atopic disease","volume":"48","author":"Aalberse","year":"1993","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.02.029_bib35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2222.2011.03804.x","article-title":"Mechanisms of immunotherapy to aeroallergens","volume":"41","author":"Shamji","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.02.029_bib36","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jaci.2016.01.057","article-title":"IgG4 to 91 allergenic molecules in early childhood by route of exposure and current and future IgE sensitization: results from the Multicentric Allergy Study birth cohort","volume":"138","author":"Schwarz","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.029_bib37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/all.13138","article-title":"Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper","volume":"72","author":"Shamji","year":"2017","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919303501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919303501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:20:25Z","timestamp":1758792025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919303501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0091674919303501"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.02.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}